Last reviewed · How we verify
Ezetimibe or ezetimibe-statin combination therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ezetimibe or ezetimibe-statin combination therapy (Ezetimibe or ezetimibe-statin combination therapy) — Sin Gon Kim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ezetimibe or ezetimibe-statin combination therapy TARGET | Ezetimibe or ezetimibe-statin combination therapy | Sin Gon Kim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ezetimibe or ezetimibe-statin combination therapy CI watch — RSS
- Ezetimibe or ezetimibe-statin combination therapy CI watch — Atom
- Ezetimibe or ezetimibe-statin combination therapy CI watch — JSON
- Ezetimibe or ezetimibe-statin combination therapy alone — RSS
Cite this brief
Drug Landscape (2026). Ezetimibe or ezetimibe-statin combination therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/ezetimibe-or-ezetimibe-statin-combination-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab